Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 5/2019

01-10-2019 | Urolithiasis | Commentary

Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017”

Authors: Agnieszka Pozdzik, Naim Maalouf, Emmanuel Letavernier, Isabelle Brocheriou, Jean-Jacques Body, Benjamin Vervaet, Carl Van Haute, Johanna Noels, Romy Gadisseur, Vincent Castiglione, Frédéric Cotton, Giovanni Gambaro, Michel Daudon, Khashayar Sakhaee

Published in: Journal of Nephrology | Issue 5/2019

Login to get access

Abstract

A symposium on kidney stones and mineral metabolism held on December 2017 in Brussels, Belgium was the first international multidisciplinary conference of the International Collaborative Network on Kidney Stones and Mineral Metabolism. This meeting addressed epidemiology, underlying pathophysiological mechanisms, genetics, pathological, as well as clinical and research topics. The participants included clinicians and recognized experts in the field from Europe and the United States interacted closely during the symposium which promoted a chance to explore new frontiers in the field of kidney stone disease. This manuscript summarizes some of the major highlights of the meeting.
Literature
1.
Sakhaee K, Maalouf NM, Sinnott B (2012) Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97(6):1847–1860CrossRefPubMedPubMedCentral
2.
Romero V, Akpinar H, Assimos DG (2010) Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 12(2–3):e86–e96PubMedPubMedCentral
3.
Shuster J, Scheaffer RL (1984) Economic impact of kidney stones in white male adults. Urology 24(4):327–331CrossRefPubMed
4.
Cone EB, Hammill BG, Routh JC, Lipkin ME, Preminger GM, Schmader KE et al (2018) Disproportionate use of inpatient care by older adults with kidney stones. Urology 120:103–108CrossRefPubMedPubMedCentral
5.
Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America P (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165CrossRefPubMedPubMedCentral
6.
Zeng G, Mai Z, Xia S, Wang Z, Zhang K, Wang L et al (2017) Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int 120(1):109–116CrossRefPubMed
7.
Ramello A, Vitale C, Marangella M (2000) Epidemiology of nephrolithiasis. J Nephrol 13(Suppl 3):S45–S50PubMed
8.
Xu LHR, Adams-Huet B, Poindexter JR, Maalouf NM, Moe OW, Sakhaee K (2017) Temporal changes in kidney stone composition and in risk factors predisposing to stone formation. J Urol 197(6):1465–1471CrossRefPubMedPubMedCentral
9.
Shavit L, Ferraro PM, Johri N, Robertson W, Walsh SB, Moochhala S et al (2015) Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transpl 30(4):607–613CrossRef
10.
Daudon M (2005) [Epidemiology of nephrolithiasis in France]. Ann Urol (Paris) 39(6):209–231CrossRef
11.
Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G (2003) Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169(6):2026–2029CrossRefPubMed
12.
Daudon M, Donsimoni R, Hennequin C, Fellahi S, Le Moel G, Paris M et al (1995) Sex- and age-related composition of 10 617 calculi analyzed by infrared spectroscopy. Urol Res 23(5):319–326CrossRefPubMed
13.
Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4(4):804–811CrossRefPubMedPubMedCentral
14.
Maeda S, Naganuma T, Takemoto Y, Shoji T, Okamura M, Nakatani T (2012) Chronic kidney disease in urolithiasis patients following successful extracorporeal shockwave lithotripsy. Mol Med Rep 5(1):3–6PubMed
15.
16.
17.
Goldfarb DS, Fischer ME, Keich Y, Goldberg J (2005) A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 67(3):1053–1061CrossRefPubMed
18.
Gambaro G, Vezzoli G, Casari G, Rampoldi L, D’Angelo A, Borghi L (2004) Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 44(6):963–986CrossRefPubMed
19.
Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K (2009) Familiality of kidney stone disease in Iceland. Scand J Urol Nephrol 43(5):420–424CrossRefPubMed
20.
Guerra A, Folesani G, Nouvenne A, Ticinesi A, Allegri F, Pinelli S et al (2016) Family history influences clinical course of idiopathic calcium nephrolithiasis: case-control study of a large cohort of Italian patients. J Nephrol 29(5):645–651CrossRefPubMed
21.
Toka HR, Genovese G, Mount DB, Pollak MR, Curhan GC (2013) Frequency of rare allelic variation in candidate genes among individuals with low and high urinary calcium excretion. PLoS One 8(8):e71885CrossRefPubMedPubMedCentral
22.
Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF et al (2009) Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41(8):926–930CrossRefPubMed
23.
Yasui T, Okada A, Urabe Y, Usami M, Mizuno K, Kubota Y et al (2013) A replication study for three nephrolithiasis loci at 5q35.3, 7p14.3 and 13q14.1 in the Japanese population. J Hum Genet 58(9):588–593CrossRefPubMed
24.
Oliveira B, Kleta R, Bockenhauer D, Walsh SB (2016) Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am J Physiol Renal Physiol 311(6):F1243–F1252CrossRefPubMed
25.
26.
Michalus I, Rusinska A (2018) Rare, genetically conditioned forms of rickets: Differential diagnosis and advances in diagnostics and treatment. Clin Genet 94(1):103–114CrossRefPubMed
27.
Sayer JA, Carr G, Simmons NL (2004) Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin Sci (Lond) 106(6):549–561CrossRef
28.
Taguchi K, Yasui T, Milliner DS, Hoppe B, Chi T (2017) Genetic risk factors for idiopathic urolithiasis: a systematic review of the literature and causal network analysis. Eur Urol Focus 3(1):72–81CrossRefPubMed
29.
Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS et al (2015) Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551CrossRefPubMed
30.
Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W et al (2016) Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11(4):664–672CrossRefPubMedPubMedCentral
31.
Daga A, Majmundar AJ, Braun DA, Gee HY, Lawson JA, Shril S et al (2018) Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int 93(1):204–213CrossRefPubMed
32.
Pelle A, Cuccurullo A, Mancini C, Sebastiano R, Stallone G, Negrisolo S et al (2017) Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria. J Nephrol 30(2):219–225CrossRefPubMed
33.
Diefenhardt P, Nosko A, Kluger MA, Richter JV, Wegscheid C, Kobayashi Y et al (2018) IL-10 receptor signaling empowers regulatory T cells to control Th17 responses and protect from GN. J Am Soc Nephrol 29(7):1825–1837CrossRefPubMedPubMedCentral
34.
Cloutier J, Villa L, Traxer O, Daudon M (2015) Kidney stone analysis: “Give me your stone, I will tell you who you are!”. World J Urol 33(2):157–169CrossRefPubMed
35.
Siener R, Buchholz N, Daudon M, Hess B, Knoll T, Osther PJ et al (2016) Quality assessment of urinary stone analysis: results of a multicenter study of laboratories in Europe. PLoS One 11(6):e0156606CrossRefPubMedPubMedCentral
36.
Daudon M, Dessombz A, Frochot V, Letavernier E, Haymann JP, Jungers P, Bazin D (2016) Comprehensive morpho-constitutional analysis of urinary stones improves etiological diagnosis and therapeutic strategy of nephrlithiasis. C R Chim 19:1470–1491CrossRef
37.
Reveillaud RJ, Daudon M, Protat MF, Ayrole G (1980) Analysis of urinary calculi in adults. Attempt of correlations between morphology and composition. Eur Urol 6(3):161–165CrossRefPubMed
38.
Daudon M, Estepa L, Lacour B, Jungers P (1998) Unusual morphology of calcium oxalate calculi in primary hyperoxaluria. J Nephrol 11(Suppl 1):51–55PubMed
39.
Sakhaee K, Maalouf NM (2008) Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 28(2):174–180CrossRefPubMed
40.
Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K (2007) Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2(5):883–888CrossRefPubMed
41.
42.
Goldfarb DS, Hirsch J. Hypothesis (2015) Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stones. Med Hypotheses 85(6):953–957CrossRefPubMedPubMedCentral
43.
Ferraro PM, Curhan GC, D’Addessi A, Gambaro G (2017) Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol 30(2):227–233CrossRefPubMed
44.
Vervaet BA, Verhulst A, D’Haese PC, De Broe ME (2009) Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transpl 24(7):2030–2035CrossRef
45.
Vervaet BA, D’Haese PC, De Broe ME, Verhulst A (2009) Crystalluric and tubular epithelial parameters during the onset of intratubular nephrocalcinosis: illustration of the ‘fixed particle’ theory in vivo. Nephrol Dial Transpl 24(12):3659–3668CrossRef
46.
Vervaet BA, Verhulst A, De Broe ME, D’Haese PC (2010) The tubular epithelium in the initiation and course of intratubular nephrocalcinosis. Urol Res 38(4):249–256CrossRefPubMed
47.
Verhulst A, Asselman M, De Naeyer S, Vervaet BA, Mengel M, Gwinner W et al (2005) Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int 68(4):1643–1647CrossRefPubMed
48.
Letavernier E, Vandermeersch S, Traxer O, Tligui M, Baud L, Ronco P et al (2015) Demographics and characterization of 10,282 Randall plaque-related kidney stones: a new epidemic? Medicine (Baltimore) 94(10):e566CrossRef
49.
Verrier C, Bazin D, Huguet L, Stephan O, Gloter A, Verpont MC et al (2016) Topography, composition and structure of incipient randall plaque at the nanoscale level. J Urol 196(5):1566–1574CrossRefPubMed
50.
51.
Letavernier E, Daudon M. Stones (2016) Tolvaptan might prevent kidney stone formation. Nat Rev Urol 13(3):130–131CrossRefPubMed
52.
Letavernier E, Kauffenstein G, Huguet L, Navasiolava N, Bouderlique E, Tang E et al (2018) ABCC6 deficiency promotes development of randall plaque. J Am Soc Nephrol 29:2337–2347CrossRef
53.
Kumakura S, Nakaya I, Sakuma T, Sato H, Soma J (2016) Crystalline cast nephropathy in a patient with IgD lambda myeloma. Clin Exp Nephrol 20(3):491–492CrossRefPubMed
54.
Gupta V, El Ters M, Kashani K, Leung N, Nasr SH (2015) Crystalglobulin-induced nephropathy. J Am Soc Nephrol 26(3):525–529CrossRefPubMed
55.
Chatchen S, Pongsakul N, Srisomsap C, Chiangjong W, Hongeng S, Svasti J et al (2018) Unravelling pathophysiology of crystalline nephropathy in ceftriaxone-associated acute kidney injury: a cellular proteomic approach. Nephron 139(1):70–82CrossRefPubMed
56.
Carbone LG, Bendixen B, Appel GB (1988) Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 12(1):72–75CrossRefPubMed
57.
Sawyer MH, Webb DE, Balow JE, Straus SE (1988) Acyclovir-induced renal failure. Clinical course and histology. Am J Med 84(6):1067–1071CrossRefPubMed
58.
Nasr SH, Milliner DS, Wooldridge TD, Sethi S (2014) Triamterene crystalline nephropathy. Am J Kidney Dis 63(1):148–152CrossRefPubMed
59.
Santoriello D, Al-Nabulsi M, Reddy A, Salamera J, D’Agati VD, Markowitz GS (2017) Atazanavir-associated crystalline nephropathy. Am J Kidney Dis 70(4):576–580CrossRefPubMed
60.
Daudon M, Frochot V, Bazin D, Jungers P (2018) Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs 78(2):163–201CrossRefPubMed
61.
Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A et al (2011) Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol 6(8):1895–1902CrossRefPubMedPubMedCentral
62.
Chuang YW, Wen MC, Wu MJ, Shu KH, Cheng CH, Yu TM et al (2012) Follow-up and treatment of renal transplantation with nephropathic cystinosis in central Taiwan. Transpl Proc 44(1):80–82CrossRef
63.
Ceballos-Picot I, Perignon JL, Hamet M, Daudon M, Kamoun P (1992) 2,8-Dihydroxyadenine urolithiasis, an underdiagnosed disease. Lancet 339(8800):1050–1051CrossRefPubMed
64.
Bollee G, Cochat P, Daudon M (2015) Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis 2:31CrossRefPubMedPubMedCentral
65.
Fogazzi GB (1996) Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transpl 11(2):379–387CrossRef
66.
Daudon M, Frochot V (2015) Crystalluria. Clin Chem Lab Med 53(Suppl 2):s1479–87PubMed
67.
Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z (2016) Urinary stone disease: advancing knowledge, patient care, and population health. Clin J Am Soc Nephrol 11(7):1305–1312CrossRefPubMedPubMedCentral
68.
Tasian GE, Ross ME, Song L, Sas DJ, Keren R, Denburg MR et al (2016) Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol 11(3):488–496CrossRefPubMedPubMedCentral
69.
Jungers P, Joly D, Barbey F, Choukroun G, Daudon M (2004) ESKD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 44(5):799–805CrossRefPubMed
70.
71.
Denburg MR, Jemielita TO, Tasian GE, Haynes K, Mucksavage P, Shults J et al (2016) Assessing the risk of incident hypertension and chronic kidney disease after exposure to shock wave lithotripsy and ureteroscopy. Kidney Int 89(1):185–192CrossRefPubMedPubMedCentral
72.
El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd et al (2012) Urolithiasis and the risk of ESKD. Clin J Am Soc Nephrol 7(9):1409–1415CrossRefPubMedPubMedCentral
73.
Gambaro G, Croppi E, Bushinsky D, Jaeger P, Cupisti A, Ticinesi A et al (2017) The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J Urol 198(2):268–273CrossRefPubMed
74.
Spatola L, Angelini C, Badalamenti S, Maringhini S, Gambaro G (2017) Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences. Urolithiasis 45(5):457–460CrossRefPubMed
75.
Worcester EM, Parks JH, Evan AP, Coe FL (2006) Renal function in patients with nephrolithiasis. J Urol 176(2):600–603 (discussion 3) CrossRefPubMed
76.
Connors BA, Evan AP, Willis LR, Blomgren PM, Lingeman JE, Fineberg NS (2000) The effect of discharge voltage on renal injury and impairment caused by lithotripsy in the pig. J Am Soc Nephrol 11(2):310–318PubMed
77.
Petrucci I, Clementi A, Sessa C, Torrisi I, Meola M (2018) Ultrasound and color Doppler applications in chronic kidney disease. J Nephrol 31(6):863–879CrossRefPubMed
78.
Zerwekh JE, Hwang TI, Poindexter J, Hill K, Wendell G, Pak CY (1988) Modulation by calcium of the inhibitor activity of naturally occurring urinary inhibitors. Kidney Int 33(5):1005–1008CrossRefPubMed
79.
Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139(4):679–684CrossRefPubMed
80.
Norman DA, Zerwekh JE, Pak CY (1981) An apparent 1,25-dihydroxyvitamin D-independent stimulation of intestinal calcium absorption in patients with Paget disease of bone during a short-term diphosphonate therapy. Metabolism 30(3):290–292CrossRefPubMed
81.
Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y et al (2012) Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 97(3):E423–E427CrossRefPubMedPubMedCentral
82.
Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM et al (2008) Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19(6):1197–1203CrossRefPubMedPubMedCentral
83.
Ricagno S, Jonsson S, Richards N, Lindqvist Y (2003) Formyl-CoA transferase encloses the CoA binding site at the interface of an interlocked dimer. EMBO J 22(13):3210–3219CrossRefPubMedPubMedCentral
84.
Siener R, Bangen U, Sidhu H, Honow R, von Unruh G, Hesse A (2013) The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int 83(6):1144–1149CrossRefPubMed
85.
Maalouf NM, Moe OW, Adams-Huet B, Sakhaee K (2011) Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab 96(12):3733–3740CrossRefPubMedPubMedCentral
86.
Ticinesi A, Guerra A, Allegri F, Nouvenne A, Cervellin G, Maggio M et al (2018) Determinants of calcium and oxalate excretion in subjects with calcium nephrolithiasis: the role of metabolic syndrome traits. J Nephrol 31(3):395–403CrossRefPubMed
87.
Adami S, Marcocci C, Gatti D (2002) Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17(Suppl 2):N18–N23PubMed
88.
Bilezikian JP, Silverberg SJ (2004) Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 350(17):1746–1751CrossRefPubMed
89.
Lal G, Clark OH (2003) Primary hyperparathyroidism: controversies in surgical management. Trends Endocrinol Metab 14(9):417–422CrossRefPubMed
90.
Bilezikian JP, Potts JT Jr, Fuleihan Gel H, Kleerekoper M, Neer R, Peacock M et al (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87(12):5353–5361CrossRefPubMed
91.
Bilezikian JP, Potts JT Jr (2002) Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future. J Bone Miner Res 17(Suppl 2):N57–N67PubMed
92.
Ruda JM, Hollenbeak CS, Stack BC Jr (2005) Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 132(3):359–372CrossRefPubMed
93.
Daudon M, Lacour B, Jungers P (2006) Influence of body size on urinary stone composition in men and women. Urol Res 34(3):193–199CrossRefPubMed
94.
Sakhaee K (2008) Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 17(3):304–309CrossRefPubMed
95.
96.
97.
Daudon M, Traxer O, Conort P, Lacour B, Jungers P (2006) Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 17(7):2026–2033CrossRefPubMed
98.
Fernandez A, Fuller A, Al-Bareeq R, Nott L, Razvi H (2013) A comparison of the metabolic profiles of diabetic and non-diabetic uric acid stone formers. Can Urol Assoc J 7(3–4):E190–E192CrossRefPubMedPubMedCentral
99.
Nikiforova VJ, Giesbertz P, Wiemer J, Bethan B, Looser R, Liebenberg V et al (2014) Glyoxylate, a new marker metabolite of type 2 diabetes. J Diabetes Res 2014:685204CrossRefPubMedPubMedCentral
100.
Burdin DV, Kolobov AA, Brocker C, Soshnev AA, Samusik N, Demyanov AV et al (2016) Diabetes-linked transcription factor HNF4alpha regulates metabolism of endogenous methylarginines and beta-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2. Sci Rep 6:35503CrossRefPubMedPubMedCentral
101.
Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ (1997) Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126(7):497–504CrossRefPubMed
102.
Sakhaee K, Poindexter JR, Griffith CS, Pak CY (2004) Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J Urol 172(3):958–961CrossRefPubMed
103.
Karp HJ, Ketola ME, Lamberg-Allardt CJ (2009) Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women. Br J Nutr 102(9):1341–1347CrossRefPubMed
104.
Green JH, Booth C, Bunning R (2003) Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption. Eur J Clin Nutr 57(1):61–68CrossRefPubMed
105.
Ketha H, Singh RJ, Grebe SK, Bergstralh EJ, Rule AD, Lieske JC et al (2015) Altered calcium and vitamin D homeostasis in first-time calcium kidney stone-formers. PLoS One 10(9):e0137350CrossRefPubMedPubMedCentral
106.
Hu H, Zhang J, Lu Y, Zhang Z, Qin B, Gao H et al. Association between circulating vitamin D Level and urolithiasis: a systematic review and meta-analysis. Nutrients. 2017;9(3):301CrossRefPubMedCentral
107.
108.
Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ et al (2011) Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery 149(5):654–661CrossRefPubMedPubMedCentral
109.
Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG (2015) Kidney stones are common after bariatric surgery. Kidney Int 87(4):839–845CrossRefPubMed
110.
Canales BK, Hatch M (2014) Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies. Surg Obes Relat Dis 10(4):734–742CrossRefPubMedPubMedCentral
111.
Pareek G, Armenakas NA, Panagopoulos G, Bruno JJ, Fracchia JA (2005) Extracorporeal shock wave lithotripsy success based on body mass index and Hounsfield units. Urology 65(1):33–36CrossRefPubMed
112.
Castiglione V, Jouret F, Bruyere O, Dubois B, Thomas A, Waltregny D et al (2015) [Epidemiology of urolithiasis in Belgium on the basis of a morpho-constitutional classification]. Nephrol Ther 11(1):42–49CrossRefPubMed
113.
114.
Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CY (1993) The potential role of salt abuse on the risk for kidney stone formation. J Urol 150(2 Pt 1):310–312CrossRefPubMed
115.
Sakhaee K, Williams RH, Oh MS, Padalino P, Adams-Huet B, Whitson P et al (1993) Alkali absorption and citrate excretion in calcium nephrolithiasis. J Bone Miner Res 8(7):789–794CrossRefPubMed
116.
Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E et al (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29(6):715–734CrossRefPubMedPubMedCentral
Metadata
Title
Meeting report of the “Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017”
Authors
Agnieszka Pozdzik
Naim Maalouf
Emmanuel Letavernier
Isabelle Brocheriou
Jean-Jacques Body
Benjamin Vervaet
Carl Van Haute
Johanna Noels
Romy Gadisseur
Vincent Castiglione
Frédéric Cotton
Giovanni Gambaro
Michel Daudon
Khashayar Sakhaee
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2019
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-019-00587-1

Other articles of this Issue 5/2019

Journal of Nephrology 5/2019 Go to the issue

Original Article

Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1

Review

When kidneys and lungs suffer together

Commentary

Calciphylaxis: a conundrum for patients and nephrologists?

Correction

Correction to: Role of anemia and proteinuria in the development of subsequent renal function deterioration in a general population with preserved glomerular filtration rate: a community-based cohort study

Editorial

Homocysteine and chronic kidney disease: an ongoing narrative

Review

Updates on urinary tract infections in kidney transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits